Quest Diagnostics announced that Sam Samad, the company's Executive Vice President and CFO, will present on the company's strategy, performance, and market trends at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 14, 2026. The session will include a fireside chat and Q&A, and will be webcast live with an archived version available until October 12, 2026. This event offers investors insight into Quest Diagnostics' business outlook and healthcare market developments. Quest Diagnostics is a major diagnostic services provider serving half of U.S. physicians and hospitals.
Quest Diagnostics announced that CEO Jim Davis will present the company's strategy, performance, and insights on market trends at the Baird 2026 Global Healthcare Conference in New York on September 15, 2026. The session will include a fireside chat ...
Humanity Health Inc. and Quest Diagnostics have launched the Humanity Biological Age test in the U.S. through Quest's consumer platform questhealth.com. For $29, individuals can add this test to select health profiles without extra blood draws, recei...
Digi Power X Inc insiders, including President Amar Alec and CEO Michel Amar, purchased shares in recent open-market transactions. Alec bought 10,000 shares at an average price of $3.86, while Amar acquired 20,000 shares at $3.60 each. These purchase...
Quest Diagnostics announced two advancements in its Quest AD-Detect® blood tests for Alzheimer's disease. The company will add the FDA-cleared Elecsys® pTau217 test, the first single-assay blood test for amyloid pathology, to its portfolio by late 20...
